- $9.16bn
- $9.53bn
- $1.53bn
- 99
- 19
- 81
- 74
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 29.08 | ||
| PEG Ratio (f) | 1.01 | ||
| EPS Growth (f) | 40.49% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 12.7 | ||
| Price to Tang. Book | 16.13 | ||
| Price to Free Cashflow | 47.44 | ||
| Price to Sales | 6 | ||
| EV to EBITDA | 27.33 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 23.36% | ||
| Return on Equity | 23.43% | ||
| Operating Margin | 20.3% | ||
Financial Summary
| Year End 3rd Jan | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,239.15 | 2,035.8 | 1,275.5 | 1,395.2 | 1,526.9 | 1,625.3 | 1,749.09 | 5.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -3.66 | -29.1 | -18.37 | -86.51 | +1159.14 | +50.61 | +12.19 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.
Directors
- Joseph Kiani CHM (56)
- Micah Young CFO (42)
- Bilal Muhsin COO (40)
- Tom McClenahan EVP (48)
- Tao Levy EVP (47)
- H Michael Cohen IND (55)
- Adam Mikkelson IND (42)
- Craig Reynolds IND (72)
- Julie Shimer IND (68)
- Last Annual
- January 3rd, 2026
- Last Interim
- January 3rd, 2026
- Incorporated
- May 7th, 1996
- Public Since
- August 8th, 2007
- No. of Shareholders
- 26
- No. of Employees
- 2,200
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 52,204,370
- Address
- 52 Discovery, IRVINE, 92618
- Web
- https://www.masimo.com/
- Phone
- +1 9492977000
- Contact
- Eli Kammerman
- Auditors
- Grant Thornton LLP
Latest News for MASI
Upcoming Events for MASI
Masimo Corp Annual Shareholders Meeting
Q1 2026 Masimo Corp Earnings Release
Q2 2026 Masimo Corp Earnings Release
Similar to MASI
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
Angiodynamics
NASDAQ Global Select Market
FAQ
As of Today at 20:55 UTC, shares in Masimo are trading at $175.49. This share price information is delayed by 15 minutes.
Shares in Masimo last closed at $175.49 and the price had moved by +5.91% over the past 365 days. In terms of relative price strength the Masimo share price has underperformed the S&P500 Index by -9.95% over the past year.
The overall consensus recommendation for Masimo is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMasimo does not currently pay a dividend.
Masimo does not currently pay a dividend.
Masimo does not currently pay a dividend.
To buy shares in Masimo you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $175.49, shares in Masimo had a market capitalisation of $9.16bn.
Here are the trading details for Masimo:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MASI
Based on an overall assessment of its quality, value and momentum Masimo is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Masimo is $176.68. That is 0.68% above the last closing price of $175.49.
Analysts covering Masimo currently have a consensus Earnings Per Share (EPS) forecast of $5.90 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Masimo. Over the past six months, its share price has outperformed the S&P500 Index by +18.72%.
As of the last closing price of $175.49, shares in Masimo were trading +16.62% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Masimo PE ratio based on its reported earnings over the past 12 months is 29.08. The shares last closed at $175.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Masimo's management team is headed by:
- Joseph Kiani - CHM
- Micah Young - CFO
- Bilal Muhsin - COO
- Tom McClenahan - EVP
- Tao Levy - EVP
- H Michael Cohen - IND
- Adam Mikkelson - IND
- Craig Reynolds - IND
- Julie Shimer - IND